Fertility and Sterility
Volume 87, Issue 3 , Pages 591-596, March 2007

Impact of infertility drugs after treatment of borderline ovarian tumors: results of a retrospective multicenter study

  • Anne Fortin, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Centre Hospitalier Universitaire Bichat, Paris, France
  • ,
  • Philippe Morice, M.D.

      Affiliations

    • Gynecologic Surgery, Institut Gustave Roussy, Villejuif, France
    • Corresponding Author InformationReprint requests: Philippe Morice, M.D., Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France (FAX: 33.1.42.11.52.13).
  • ,
  • Anne Thoury, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Centre Hospitalier Universitaire Bichat, Paris, France
  • ,
  • Sophie Camatte, M.D.

      Affiliations

    • Gynecologic Surgery, Institut Gustave Roussy, Villejuif, France
  • ,
  • Caroline Dhainaut, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Centre Hospitalier Universitaire Bichat, Paris, France
  • ,
  • Patrick Madelenat, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Centre Hospitalier Universitaire Bichat, Paris, France

Received 27 February 2006; received in revised form 20 July 2006; accepted 20 July 2006. published online 16 November 2006.

Objective

To evaluate safety and fertility outcome after the use of infertility drugs in patients who were treated conservatively for a borderline ovarian tumor (BOT).

Design

A retrospective multicenter study.

Setting

Centers participating in the French National Register on In Vitro Fertilization registry.

Patient(s)

Thirty patients who were treated for BOT who underwent ovarian induction (OI).

Intervention(s)

Ovarian induction was performed in 25 patients for infertility after conservative surgery and before surgery for recurrent disease in 5 patients with a single ovary (emergency cases).

Main Outcomes Measure(s)

Fertility and recurrences rates.

Result(s)

The mean number of cycles of OI per patient was 2.6 (range, 1–10 cycles). The median follow-up time after treatment of the BOT was 93 months (range, 26–276 months). After a median follow-up time of 42 months after OI, 4 recurrences were observed (initial management was simple cystectomy in 3 of them). All recurrences were borderline tumors on a remaining ovary that had been treated by surgery alone. All patients are currently disease-free. Thirteen pregnancies were observed (10 pregnancies (40%) in the group of 25 patients who were treated for infertility).

Conclusion(s)

These results suggest that infertility drugs could be used safely in patients who experience infertility after conservative management of an early-stage BOT.

Key Words: Borderline tumor, conservative treatment, infertility, in vitro fertilization, pregnancy, recurrence

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0015-0282(06)04009-X

doi:10.1016/j.fertnstert.2006.07.1503

Fertility and Sterility
Volume 87, Issue 3 , Pages 591-596, March 2007